FI3386506T3 - Kv3-kanavien modulaattoreita kivun hoitamiseksi - Google Patents

Kv3-kanavien modulaattoreita kivun hoitamiseksi Download PDF

Info

Publication number
FI3386506T3
FI3386506T3 FIEP16813020.1T FI16813020T FI3386506T3 FI 3386506 T3 FI3386506 T3 FI 3386506T3 FI 16813020 T FI16813020 T FI 16813020T FI 3386506 T3 FI3386506 T3 FI 3386506T3
Authority
FI
Finland
Prior art keywords
tai
metyyli
yyli
etyyli
oksi
Prior art date
Application number
FIEP16813020.1T
Other languages
English (en)
Finnish (fi)
Inventor
Charles Large
Giuseppe Alvaro
Original Assignee
Autifony Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autifony Therapeutics Ltd filed Critical Autifony Therapeutics Ltd
Application granted granted Critical
Publication of FI3386506T3 publication Critical patent/FI3386506T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00Ethers; Compounds having groups, groups or groups
    • C07C43/30Compounds having groups
    • C07C43/315Compounds having groups containing oxygen atoms singly bound to carbon atoms not being acetal carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
FIEP16813020.1T 2015-12-10 2016-12-09 Kv3-kanavien modulaattoreita kivun hoitamiseksi FI3386506T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1521751.6A GB201521751D0 (en) 2015-12-10 2015-12-10 Novel uses
PCT/GB2016/053879 WO2017098254A1 (en) 2015-12-10 2016-12-09 Modulators of kv3 channels to treat pain

Publications (1)

Publication Number Publication Date
FI3386506T3 true FI3386506T3 (fi) 2024-04-23

Family

ID=55274489

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP16813020.1T FI3386506T3 (fi) 2015-12-10 2016-12-09 Kv3-kanavien modulaattoreita kivun hoitamiseksi

Country Status (20)

Country Link
US (3) US11147813B2 (enExample)
EP (1) EP3386506B1 (enExample)
JP (3) JP7149847B2 (enExample)
KR (1) KR102812887B1 (enExample)
CN (2) CN108472288B (enExample)
AU (1) AU2016367239B2 (enExample)
BR (1) BR112018011700B1 (enExample)
DK (1) DK3386506T3 (enExample)
EA (1) EA038059B1 (enExample)
ES (1) ES2974902T3 (enExample)
FI (1) FI3386506T3 (enExample)
GB (1) GB201521751D0 (enExample)
HR (1) HRP20240497T1 (enExample)
HU (1) HUE066879T2 (enExample)
IL (1) IL259717B (enExample)
MX (1) MX385578B (enExample)
PL (1) PL3386506T3 (enExample)
PT (1) PT3386506T (enExample)
SG (1) SG11201804123VA (enExample)
WO (1) WO2017098254A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201613163D0 (en) 2016-07-29 2016-09-14 Autifony Therapeutics Ltd Novel compounds
EP3555073A1 (en) 2016-12-16 2019-10-23 Autifony Therapeutics Limited Hydantoin modulators of kv3 channels
WO2018220762A1 (ja) 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
US12358901B2 (en) 2018-10-16 2025-07-15 Autifony Therapeutics Limited KV3 modulators
KR102854594B1 (ko) 2018-10-16 2025-09-02 오티포니 세라피틱스 리미티드 신규한 화합물
TW202031645A (zh) * 2018-10-30 2020-09-01 丹麥商H 朗德貝克公司 作為Kv3鉀通道激活劑之芳基磺醯基吡咯甲醯胺衍生物
NZ775496A (en) 2018-11-30 2026-01-30 Otsuka Pharma Co Ltd Heterocyclic compounds for the treatment of epilepsy
MX2022009702A (es) 2020-02-06 2022-09-07 Autifony Therapeutics Ltd Moduladores de kv3.
MX2024001899A (es) 2021-08-10 2024-03-01 Autifony Therapeutics Ltd Moduladores del canal de potasio.
CN113788741B (zh) * 2021-09-28 2023-12-29 大连九信精细化工有限公司 一种制备2-环丙基苯酚衍生物的方法
EP4630117A1 (en) 2022-12-06 2025-10-15 Autifony Therapeutics Limited Compounds for the treatment of centra nervous system disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201001855A1 (ru) 2008-06-06 2011-08-30 Юсб Фарма, С.А. Соединения, содержащие циклобутоксигруппу
PL2509961T3 (pl) * 2009-12-11 2016-09-30 Pochodne imidazolidynodionu
ES2560304T3 (es) * 2010-12-06 2016-02-18 Autifony Therapeutics Limited Derivados de hidantoína útiles como inhibidores de Kv3
GB201209986D0 (en) 2012-06-06 2012-07-18 Autifony Therapeutics Ltd Novel compounds
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
CN103974944B (zh) * 2011-12-06 2016-11-02 奥蒂福尼疗法有限公司 用作kv3抑制剂的乙内酰脲衍生物
EP2852588B8 (en) 2012-05-22 2018-01-10 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
WO2013175215A1 (en) * 2012-05-22 2013-11-28 Autifony Therapeutics Limited Triazoles as kv3 inhibitors
WO2013182851A1 (en) 2012-06-06 2013-12-12 Autifony Therapeutics Limited Prophylaxis or treatment of diseases where a modulator of kv3.3 channels is required
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
GB201522179D0 (en) 2015-12-16 2016-01-27 Autifony Therapeutics Ltd Novel compounds

Also Published As

Publication number Publication date
IL259717B (en) 2021-05-31
US11944623B2 (en) 2024-04-02
HRP20240497T1 (hr) 2024-08-16
EP3386506B1 (en) 2024-01-24
EA201891377A1 (ru) 2019-01-31
EP3386506A1 (en) 2018-10-17
CN108472288B (zh) 2024-05-28
EA038059B1 (ru) 2021-06-30
BR112018011700A2 (pt) 2018-11-27
AU2016367239B2 (en) 2020-07-09
WO2017098254A1 (en) 2017-06-15
PL3386506T3 (pl) 2024-06-03
CN108472288A (zh) 2018-08-31
MX2018007074A (es) 2018-12-12
JP7149847B2 (ja) 2022-10-07
GB201521751D0 (en) 2016-01-27
HUE066879T2 (hu) 2024-09-28
SG11201804123VA (en) 2018-06-28
BR112018011700B1 (pt) 2023-12-26
US11147813B2 (en) 2021-10-19
PT3386506T (pt) 2024-03-28
DK3386506T3 (da) 2024-05-06
CA3005302A1 (en) 2017-06-15
JP2022141699A (ja) 2022-09-29
US20190000848A1 (en) 2019-01-03
ES2974902T3 (es) 2024-07-02
MX385578B (es) 2025-03-18
US20220071998A1 (en) 2022-03-10
JP2025003958A (ja) 2025-01-14
US20250017925A1 (en) 2025-01-16
KR102812887B1 (ko) 2025-05-26
JP2019506367A (ja) 2019-03-07
AU2016367239A1 (en) 2018-06-07
IL259717A (en) 2018-07-31
CN118267386A (zh) 2024-07-02
KR20180097549A (ko) 2018-08-31

Similar Documents

Publication Publication Date Title
CL2021000566A1 (es) Procesos para fabricar ácido 2-((3r,5r,6s)-5-(3-clorofenil)-6-(4-clorofenil)-1-((s)-1-(isopropilsulfonil)-3-metilbutan-2-il)-3-metil-2-oxopiperidin-3-il)acético, intermediarios y procesos para fabricar los intermediarios, formas cristalinas del compuesto y los intermediarios. (divisional de la solicitud no. 2015003589)
ES2998396T3 (en) Substituted tetrahydrofurans as modulators of sodium channels
WO2010027875A3 (en) Compounds that modulate intracellular calcium
AU2022297373B2 (en) Diacylglyercol kinase modulating compounds
AU2022297367A1 (en) Diacylglyercol kinase modulating compounds
WO2009035818A8 (en) Compounds that modulate intracellular calcium
WO2009076454A3 (en) Compounds that modulate intracellular calcium
MX2009009415A (es) Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
MX363118B (es) Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2).
WO2013056070A3 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EP4309736A3 (en) Crystalline forms of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido [1',2':4,5]pyrazino [2,1-b][1,3]oxazepine-10-carboxamide
AU2022299051B2 (en) Diacylglyercol kinase modulating compounds
LT4103566T (lt) Kondensuoti pirimidino junginiai, kaip kcc2 moduliatoriai
WO2017156495A8 (en) Compounds and methods for modulating bruton's tyrosine kinase
CL2017003112A1 (es) Procesos e intermediarios para la preparación de {1-(etilsulfonil)-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo.
WO2011034962A3 (en) Compounds that modulate intracellular calcium
MY200738A (en) Pyrazole magl inhibitors
PA8796001A1 (es) Moduladores tieno- y furo-pirimidina del receptor de histamina h4
MX356813B (es) Derivados de hidantoina utiles como inhibidores de kv3.
WO2011109551A3 (en) Compounds that modulate intracellular calcium
UA103468C2 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н3
EA201401268A1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ (1r,4r)-6'-ФТОР-N,N-ДИМЕТИЛ-4-ФЕНИЛ-4',9'-ДИГИДРО-3'H-СПИРО[ЦИКЛОГЕКСАН-1,1'-ПИРАНО[3,4,b]ИНДОЛ]-4-АМИН И ГАБАПЕНТИНОИД
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
EA201401265A1 (ru) Фармацевтическая композиция, содержащая (1r,4r)-6'-фтор-n,n-диметил-4-фенил-4',9'-дигидро-3'h-спиро[циклогексан-1,1'-пирано-[3,4,b]индол]-4-амин и оксикам